Products & Services · Revenue recognized
Oncology — Revenue recognized
Natera, Inc. Oncology — Revenue recognized remained flat by 0.0% to $100.00K in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
How to read this metric
An increase reflects higher volume or pricing power in the oncology diagnostic market, signaling successful commercial execution. A decrease suggests potential market share loss, pricing pressure, or reduced demand for oncology testing services.
Detailed definition
This metric measures the total revenue recognized during the reporting period specifically attributable to oncology assa...
Peer comparison
Comparable to 'Segment Revenue' or 'Product Revenue' reported by other molecular diagnostics and precision medicine companies.
Metric ID:
ntra_segment_oncology_revenue_recognizedHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $100.00K | $100.00K |
| QoQ Change | — | +0.0% |
| YoY Change | — | +0.0% |
Range$100.00K – $100.00K
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Natera, Inc.'s oncology — revenue recognized?
- Natera, Inc. (NTRA) reported oncology — revenue recognized of $100.00K in Q1 2026.
- What does oncology — revenue recognized mean?
- The total revenue generated from providing oncology-related diagnostic and interpretation services during the period.